Skip to Main Content
Try STAT+ TODAY
Trending:
First Opinion
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Politics
STAT+

Did Rep. Chris Collins sell his biotech stock without telling Congress?

  • Damian Garde

By Damian Garde Nov. 12, 2018

Reprints
Rep. Chris Collins (R-NY)
Rep. Chris Collins (R-N.Y.) Win McNamee/Getty Images

Rep. Chris Collins, the New York lawmaker facing insider trading charges, was once the No. 2 shareholder in an Australian firm called Innate Immunotherapeutics. According to the company’s most recent disclosure, he’s no longer even in the top 20 shareholders.

What’s unclear is what happened to his shares.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Who will get the call from Stockholm? It’s time…
Who will get the call from Stockholm? It’s time for STAT’s 2022 Nobel Prize predictions
Push to double up on Covid booster and flu…
Push to double up on Covid booster and flu shot may have a downside, experts caution
Even during a pandemic, hospitals must make family visits…
Even during a pandemic, hospitals must make family visits and communication the standard of care
The biotech scorecard for the fourth quarter: 14 stock-moving…
The biotech scorecard for the fourth quarter: 14 stock-moving events to watch
FDA approves ALS drug from Amylyx, giving patients a…
FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option
Listen: A surprise success in Alzheimer’s and how FDA…
Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy

Comments are closed.

Recommended Stories